IP Library Granted Patent US 11,904,024
Granted Patent B2
US 11,904,024 · App. 17/205,673 · Granted Feb 20, 2024

Eye drop composition

Inventors: Nesya Goris (Kessel-Lo, BE); Johan Neyts (Kessel-Lo, BE); Erwin Blomsma (Linden, BE); Stefaan Wera (Bierbeek, BE); Ainola Billiet (Bierbeek, BE); Joeri Auwerx (Bierbeek, BE); Veerle Debeurme (Kessel-Lo, BE); Maryline Roe (Toulouse, FR); Pascal Puig (Cazilhac, FR)
Assignee: Aratana Therapeutics, Inc.
A61K49/0004A61K9/0048A61K31/305A61K31/522A61K47/24A61K47/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,904,024
App. No.
17/205,673
Granted
Feb 20, 2024
Kind
B2
Abstract

The present invention relates to an eye-drop composition comprising 2-amino-9-[[(1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl]methyl]-1,9-dihydro-6H-Purin-6-one, and the use thereof for the diagnosis and treatment of herpetic eye infections in companion animals.

Claims (22)

1. A composition comprising:

at least 0.1% w/v 2-amino-9-[[(1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl]methyl]-1,9-dihydro-6H-Purin-6-one; and

at least 10% w/v of a cyclodextrin.

2. The composition according to claim 1 , which is an aqueous solution.

3. The composition according to claim 1 , wherein said composition is an ophthalmic solution.

4. The composition according to claim 1 , wherein said cyclodextrin is hydroxypropyl beta-cyclodextrin.

5. The composition according to claim 1 , further comprising at least 0.008% w/v thiomersal.

6. A composition according to claim 1 , for use as a diagnostic or a therapeutic composition.

7. The composition according to claim 6 , for use in a method for the treatment of an ocular herpetic infection.

8. The composition according to claim 7 , wherein said ocular infection is an ocular infection of a companion animal.

9. The composition according to claim 8 , wherein said companion animal is a feline.

10. The composition according to claim 7 , wherein said method comprises applying said composition onto the eye two or three times per day for at least seven days.

11. The composition according to claim 6 , for use in a method of diagnosis of an ocular herpetic infection.

12. The composition according to claim 10 , wherein said ocular infection is an ocular infection in a companion animal.

13. The composition according to claim 12 , wherein said companion animal is a feline.

14. A method for preparing an ophthalmic solution, comprising the steps of:

a) providing a solution comprising at least 10% w/v of a cyclodextrin;

b) adding 2-amino-9-[[(1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl]methyl]-1,9-dihydro-6H-Purin-6-one to said solution;

c) solubilizing the 2-amino-9-[[(1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl]methyl]-1,9-dihydro-6H-Purin-6-one added in step b);

d) repeating steps b) and c) until a concentration of 2-amino-9-[[(1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl]methyl]-1,9-dihydro-6H-Purin-6-one in said solution of at least 1 mg/mL is obtained;

e) optionally, adding at least 0.008 mg/mL thiomersal.

15. The method according to claim 14 , wherein said cyclodextrin is hydroxypropyl beta-cyclodextrin.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2021
From: NEYTS, JOHAN; GORIS, NESYA; BLOMSMA, ERWIN; WERA, STEFAAN; BILLIET, AINO; AUWERX, JOERI; DEBEURME, VEERLE; ROE, MARYLINE; PUIG, PASCAL
To: OKAPI SCIENCES NV
Reel/Frame 057096/0733 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2021
From: OKAPI SCIENCES NV
To: ARATANA THERAPEUTICS NV
Reel/Frame 057096/0746 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2021
From: GORIS, NESYA; NEYTS, JOHAN; BLOMSMA, ERWIN; WERA, STEFAAN; BILLIET, AINOLA; AUWERX, JOERI; DEBEURME, VEERLE; ROE, MARYLINE; PUIG, PASCAL
To: ARATANA THERAPEUTICS NV
Reel/Frame 057096/0757 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2021
From: ARATANA THERAPEUTICS NV
To: ARATANA THERAPEUTICS, INC.
Reel/Frame 057096/0767 →
Continuity (3)
Continuation 14828365 · Aug 17, 2015
Continuation 14373322
Related Publication 20210205478A1 · Jul 8, 2021